David H. Ilson, MD, PhD, discusses the main takeaway from the data for phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.
David H. Ilson, MD, PhD, attending physician and professor of medicine at Memorial Sloan Kettering Cancer Center, discusses the main takeaway from the data for the phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.
Treatment with TAS-102 (trifluridine/tipiracil; FTD/TPI; Lonsurf) modestly improved progression-free survival and overall survival in patients with refractory gastric or gastroesophageal junction (GEJ) cancer. However, Ilson says this is more of a stabilizing drug since there weren’t really any responses.
Quality of life data in the original trial also showed a slow decline in performance status with TAS-102 compared to placebo. Ilson says this will likely be a good option for patients with refractory disease who do not have other treatment options.
See more from this trial.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
2 Commerce Drive
Cranbury, NJ 08512